Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685514 | 1.00 | TK2 (0.47) | TK2PYGM | |
| SCHEMBL25971955 | 0.92 | TK2 (0.41) | TK2PYGM | |
| SCHEMBL27179233 | 0.89 | TK2 (0.49) | TK2PYGM | |
| SCHEMBL1060097 | 0.89 | TK2 (0.49) | TK2PYGM | |
| SCHEMBL1060099 | 0.89 | TK2 (0.49) | TK2PYGM | |
| SCHEMBL9132872 | 0.85 | TK2 (0.50) | TK2PYGM | |
| SCHEMBL1417684 | 0.85 | TK2 (0.50) | TK2PYGM | |
| SCHEMBL1417682 | 0.85 | TK2 (0.50) | TK2PYGM | |
| SCHEMBL9132874 | 0.85 | TK2 (0.50) | TK2PYGM | |
| SCHEMBL22992480 | 0.81 | TK2 (0.67) | TK2PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004512810-A | — | — | 2004-04-30 | — | — | JP | claimed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6617438-B1 | Nucleic acid of given formula; ribozyme able to cleave RNA of HER2 gene; use as anticarcinogenic agent | SIRNA THERAPEUTICS, INC. | 2003-09-09 | — | — | US | disclosed |
| US-6528640-B1 | Of given formula; can use to inhibit HER2/neu/ ErbB2 gene expression; anticarcinogenic agents | RIBOZYME PHARMACEUTICALS, INCORPORATED | 2003-03-04 | — | — | US | disclosed |
| US-20030004122-A1 | Nucleotide triphosphates and their incorporation into oligonucleotides | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004122-A1 | Nucleotide triphosphates and their incorporation into oligonucleotides | NTPCR, DNTT, RNGTT | TK2 21/4885PYGM 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.